Petra Reinke Selected Research

Lymphoproliferative Disorders (Lymphoproliferative Disorder)

8/2021	Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
11/2018	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
1/2018	End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry.
2/2017	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
1/2014	Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.
10/2012	Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
2/2012	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
9/2011	IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment.
7/2011	Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases.
12/2007	Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Petra Reinke Research Topics

Disease

16	Infections 06/2022 - 07/2004
13	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 08/2021 - 07/2006
11	Sepsis (Septicemia) 01/2020 - 12/2005
8	Inflammation (Inflammations) 01/2022 - 11/2006
8	Neoplasms (Cancer) 01/2021 - 07/2005
6	Disease Progression 01/2021 - 07/2006
4	Chronic Kidney Failure (Chronic Renal Failure) 06/2022 - 11/2006
4	Lymphoma (Lymphomas) 01/2018 - 08/2007
4	Septic Shock (Toxic Shock Syndrome) 03/2010 - 08/2008
3	Virus Diseases (Viral Diseases) 06/2022 - 06/2015
3	COVID-19 06/2022 - 01/2020
3	Wounds and Injuries (Trauma) 01/2022 - 12/2005
3	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 11/2019
3	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 02/2016
3	Ischemia 03/2012 - 09/2002
2	Epstein-Barr Virus Infections 11/2020 - 12/2016
2	Body Weight (Weight, Body) 10/2020 - 06/2009
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 09/2020 - 01/2020
2	Pneumonia (Pneumonitis) 01/2020 - 10/2017
2	Necrosis 11/2018 - 01/2011
2	Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) 01/2018 - 02/2016
2	Diabetes Mellitus 01/2017 - 07/2004
2	Viremia 12/2016 - 09/2015
2	Hyperuricemia 06/2016 - 07/2004
2	Hypertension (High Blood Pressure) 01/2016 - 07/2004
2	Tetanus 02/2014 - 11/2006
2	Pain (Aches) 08/2008 - 05/2004
2	Hypoxia (Hypoxemia) 01/2007 - 02/2005
2	Diabetic Nephropathies (Diabetic Nephropathy) 11/2006 - 01/2002
2	Uremia 07/2005 - 06/2004
1	Leukemia 06/2022
1	Hematologic Neoplasms (Hematological Malignancy) 06/2022
1	Delayed Graft Function 01/2022
1	Rupture 01/2022
1	Rare Diseases (Rare Disease) 01/2021
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2021
1	Critical Illness (Critically Ill) 09/2020
1	Respiratory Insufficiency (Respiratory Failure) 09/2020
1	Proteinuria 01/2020
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 09/2019
1	Heart Failure 09/2019
1	End Stage Liver Disease 01/2019
1	Immune System Diseases (Immune Disorders) 01/2019

Drug/Important Bio-Agent (IBA)

9	Rituximab (Mabthera)FDA Link 08/2021 - 04/2007
7	CytokinesIBA 06/2022 - 07/2004
6	CreatinineIBA 01/2020 - 06/2004
5	Interleukin-6 (Interleukin 6)IBA 09/2011 - 07/2004
4	Tacrolimus (Prograf)FDA LinkGeneric 06/2022 - 03/2010
4	Antiviral Agents (Antivirals)IBA 01/2019 - 11/2009
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2013 - 07/2004
4	Proteins (Proteins, Gene)FDA Link 03/2011 - 01/2007
3	AntigensIBA 06/2022 - 07/2005
3	SteroidsIBA 01/2022 - 11/2018
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2021 - 03/2011
3	AntibodiesIBA 01/2018 - 06/2013
3	Interleukin-10 (Interleukin 10)IBA 09/2011 - 11/2006
3	Tryptophan (L-Tryptophan)FDA Link 08/2011 - 06/2009
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 03/2010 - 10/2009
3	HLA-DR Antigens (HLA-DR)IBA 10/2009 - 12/2005
3	Codon (Codons)IBA 12/2006 - 07/2004
2	VaccinesIBA 06/2022 - 02/2014
2	HLA Antigens (Human Leukocyte Antigens)IBA 06/2022 - 03/2010
2	LigandsIBA 01/2021 - 08/2013
2	Calcineurin InhibitorsIBA 11/2018 - 01/2007
2	EnzymesIBA 02/2018 - 01/2007
2	Neurotransmitter Receptors (Neurotransmitter Receptor)IBA 01/2018 - 02/2016
2	AutoantibodiesIBA 01/2018 - 02/2016
2	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2017 - 10/2012
2	Prednisone (Sone)FDA LinkGeneric 02/2017 - 10/2012
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2017 - 10/2012
2	Vincristine (Oncovin)FDA LinkGeneric 02/2017 - 10/2012
2	Uric Acid (Urate)IBA 06/2016 - 01/2016
2	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 06/2013 - 03/2012
2	InterferonsIBA 03/2013 - 01/2011
2	Kynurenic Acid (Kynurenate)IBA 08/2011 - 03/2010
2	Quinolinic AcidIBA 08/2011 - 03/2010
2	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 03/2010 - 06/2009
2	Oxygen (Dioxygen)IBA 01/2007 - 02/2005
2	Transforming Growth Factor beta1 (TGF beta 1)IBA 12/2006 - 11/2006
2	Transforming Growth Factor beta (TGF-beta)IBA 12/2006 - 07/2004
1	Chimeric Antigen ReceptorsIBA 06/2022
1	Cytochrome P-450 CYP3AIBA 01/2022
1	ChemokinesIBA 01/2021
1	cyclic adenosine-5'-trimetaphosphate (ATMP)IBA 01/2021
1	Thromboplastin (Tissue Factor)IBA 01/2020

Therapy/Procedure

17	Therapeutics 08/2021 - 06/2004
14	Kidney Transplantation 11/2020 - 07/2005
12	Transplantation 01/2021 - 01/2007
7	Organ Transplantation 01/2020 - 07/2004
6	Drug Therapy (Chemotherapy) 01/2021 - 04/2007
3	Cell- and Tissue-Based Therapy (Cell Therapy) 06/2022 - 01/2018
3	Hematopoietic Stem Cell Transplantation 01/2022 - 11/2019
2	Nephrectomy 01/2016 - 12/2011
2	Renal Dialysis (Hemodialysis) 05/2014 - 11/2006
2	Critical Care (Surgical Intensive Care) 09/2013 - 08/2008
1	Radiotherapy 08/2021
1	Neoadjuvant Therapy 01/2021
1	Artificial Respiration (Mechanical Ventilation) 09/2020
1	Liver Transplantation 01/2019
1	Injections 12/2018